Patents Examined by Karen Cochrane Carlson
  • Patent number: 11485773
    Abstract: A genetically engineered live bacterium which is adapted to selectively replicate in and colonize a selected tissue type within the mammal, and concurrently produce within the selected tissue type at least one protease-sensitive cytotoxic molecule which is degradable by proteases within the selected tissue type, and at least one protease inhibitor peptide to inhibit the proteases within the selected tissue type from proteolytically degrading the protease sensitive cytotoxic molecule. The combination results in higher concentrations of the cytotoxic molecule local to the colonization, while permitting protease degradation of the cytotoxic molecule further away from the colonization.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: November 1, 2022
    Inventor: David Gordon Bermudes
  • Patent number: 11485760
    Abstract: Cas9-inhibiting polypeptide compositions and methods are provided.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: November 1, 2022
    Assignee: The Regents of the University of California
    Inventors: Joseph Bondy-Denomy, Benjamin Rauch
  • Patent number: 11479792
    Abstract: Provided herein are compositions and methods to make and use engineered cells, for the purpose of increasing the cell density of a culture comprising metazoan cells and for the production of a cultured edible product.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: October 25, 2022
    Assignee: Upside Foods, Inc.
    Inventors: Nicholas J. Genovese, Eric N. Schulze, Danielle N. Desmet
  • Patent number: 11471494
    Abstract: Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: October 18, 2022
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Jonathan W. Kotula, Vincent M. Isabella, Paul F. Miller, Suman Machinani, Saurabh Saha, Adam B. Fisher, Yves Millet, Ning Li, Jose M. Lora
  • Patent number: 11466069
    Abstract: The present invention provides novels method of targeting delivery of a compound to hypoxic cells, for example treatment of diseases and disorders associated with hypoxia, comprising administration of a construct comprising a targeting carrier peptide and a compound for delivery to a hypoxic cell. The invention also provides novel methods for the treatment of diseases or disorders of the eye by administration of a novel construct, a nucleic acid encoding a novel construct, and/or a nucleic acid vector comprising a nucleic acid encoding a novel construct. The invention further provides novel constructs, nucleic acids encoding such constructs, and/or nucleic acid vectors comprising nucleic acids encoding such constructs.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: October 11, 2022
    Assignee: AUCKLAND UNISERVICES LIMITED
    Inventors: Colin Richard Green, Frazer Paul Coutinho, Ilva Dana Rupenthal
  • Patent number: 11464807
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: October 11, 2022
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Patent number: 11466056
    Abstract: The present invention is directed to a recombinant herpesvirus comprising a heterologous peptide and optionally polypeptide ligand capable of binding to (a) target molecule(s) and fused to or inserted into glycoprotein D. The recombinant herpesvirus may additionally comprise modifications for detargeting the virus from the natural receptors of gD. This allows the herpesvirus to efficiently target a cell for therapeutic purposes and a cell for virus production. The present invention further comprises a pharmaceutical composition comprising the herpesvirus, the herpesvirus for use in the treatment of a tumor, infection, degenerative disorder or senescence-associated disease, a nucleic acid and a vector coding for the gD, a polypeptide comprising the gD, and a cell comprising the herpesvirus, nucleic acid, vector or polypeptide. Moreover, a method for infecting a cell with the herpesvirus or for producing the herpesvirus is disclosed.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: October 11, 2022
    Assignee: ALMA MATER STUDIORUM—UNIVERSITÀ DI BOLOGNA
    Inventors: Valerio Leoni, Maria Gabriella Campadelli
  • Patent number: 11458171
    Abstract: The present disclosure provides an engineered stem cell, comprising a vector comprising a polynucleotide comprising a nucleic acid sequence of suicide gene, a nucleic acid sequence of immune checkpoint gene and a natural cytotoxicity triggering receptor or a TNF-related apoptosis-inducing ligand, wherein the stem cell is a tumor-targeting cell. The present disclosure also provides a method for treating a cancer or enhancing intratumor immunity or enhancing immunity in tumor microenvironment in a subject, comprising administering an effective amount of the engineered stem cell of the present disclosure to the subject.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: October 4, 2022
    Assignee: CHINA MEDICAL UNIVERSITY
    Inventors: Woei-Cherng Shyu, Chen-Huan Lin, Wei Lee, Chien-Lin Chen, Long-Bin Jeng, Chang-Hai Tsai
  • Patent number: 11447757
    Abstract: The present disclosure relates to methods for using one or more polypeptides with phytase activity in grain processing, ethanol, and biofuel production.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: September 20, 2022
    Assignee: BASF ENZYMES LLC
    Inventors: Danielle Cusumano, Tony Newton, Arne I. Solbak
  • Patent number: 11446384
    Abstract: The present invention relates to a heart targeting agent comprising tannic acid, in which the agent aids a heart disease therapeutic drug to be delivered to the heart and bind to the cardiac myocardium by inducing tannylation of the drug so as to make heart targeting and accumulation of the drug possible. Unlike the conventional invasive method used for the traditional drugs to be able to target the heart, the agent of the present invention can help a drug to target the heart with high efficiency just via non-invasive intravenous administration.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: September 20, 2022
    Inventors: Ki-Suk Kim, Hyang-Ae Lee, Sun Hyun Park, Haeshin Lee, Mikyung Shin
  • Patent number: 11446398
    Abstract: The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: September 20, 2022
    Assignee: OBSIDIAN THERAPEUTICS, INC.
    Inventors: Peter Barrett, Michael N. Gladstone, Tariq A. Kassum, Vipin Suri, Dan Jun Li, Dexue Sun, Brian Dolinski
  • Patent number: 11439692
    Abstract: The present invention provides a method of treating a disease associated with activated MYD88 signaling in a subject, including suppressing MYD88 expression in a subject by targeting an expression regulatory region of MYD88 gene by using a CRISPR-Guide Nucleotide Directed Modulation (GNDM), without affecting the expression of an adjacent ACAA1 gene. Also, provided is a CRISPR-GNDM system for suppressing MYD88, including expression comprising (a) a protein selected from the group consisting of dCas9 or dCpf1, a fusion protein of dCas9 or dCpf1 and Kruppel associated box (KRAB) and (b) a guide RNA (gRNA) targeting an expression regulatory region of MYD88 gene.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: September 13, 2022
    Assignee: Modalis Therapeutics Corporation
    Inventors: Tetsuya Yamagata, Yuanbo Qin, Iain Robert Thompson, Haruhiko Morita
  • Patent number: 11441136
    Abstract: The present invention relates to polypeptide variants and methods for obtaining variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: September 13, 2022
    Assignee: Novozymes A/S
    Inventors: Lars Henrik Oestergaard, Lars Giger, Annette Helle Johansen, Lars Beier, Jurgen Carsten Franz Knotzel, Gernot J. Abel, Klaus Gori
  • Patent number: 11439689
    Abstract: A method for detecting whether glucose metabolism is abnormal comprises: detecting GPx2 gene expression, GPx2 protein expression or the activity of GPx2 protein in a test body, and making comparisons with GPx2 expression amount of a normal individual, when the GPx2 expression of the individual is significantly lower than that of the normal individual, indicating that the carbohydrate metabolism of the individual is in an abnormal state. Applications of GPx2 in the preparation of a medical composition for the treatment and prevention of type II diabetes.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: September 13, 2022
    Assignee: Kaohsiung Medical University
    Inventors: Ming-Lung Yu, Wan-Long Chuang, Jee-Fu Huang, Chia-Yen Dai, Yu-Min Ko
  • Patent number: 11434474
    Abstract: The present disclosure features methods and compositions for modulating lipid metabolism to achieve improved production and quality of recombinant products, such as next generation biologics. Modulation of lipid metabolism as described herein includes, for example, introducing a lipid metabolism modulator described herein to a cell or a cell-free system. Also encompassed by the present disclosure are engineered cells with improved production capacity and improved product quality, methods for engineering such cells, and preparations and mixtures comprising the products from such cells.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: September 6, 2022
    Assignee: LONZA LTD
    Inventors: James Budge, Christopher Mark Smales, Tanya Jeane Knight, Robert Young
  • Patent number: 11427643
    Abstract: The invention relates to a method of controlling the level of a polypeptide sequence comprising administering a polypeptide sequence fused to a ubiquitin targeting protein which comprises a minimal degron structural motif. In particular, the polypeptide sequence comprises a chimeric antigen receptor therefore the present invention is useful in methods of cell and gene therapy where the activity of the chimeric antigen receptor needs to be controlled.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: August 30, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Lewis Lee Brayshaw, Michael Menteith Hann, Christopher Herring, Carlos Martinez Fleites, Markus Alexander Queisser
  • Patent number: 11421005
    Abstract: The invention provides chimeric antigen receptor(s) (CAR(s)) that comprise a fusion protein of CTX or any functional variant thereof or a CTX-like peptide or any functional variant thereof as the extracellular antigen recognition moiety of the CAR. CAR(s) comprising CTX, a CTX-like peptide or functional variants of the foregoing are collectively referred to herein as “CTX-CAR(s).” Such CTX-CAR(s) may further comprise additional moieties or domains in the extracellular domain, a transmembrane domain and at least one intracellular! signaling domain. Such CTX-CAR(s) may be expressed in a host cell, such as, but not limited to, an immune effector cell. The present invention also provides methods of treatment (such as, for example, methods for treating cancer) by providing to the patient in need thereof immune effector cells that are engineered to express a CTX-CAR described herein.
    Type: Grant
    Filed: December 9, 2017
    Date of Patent: August 23, 2022
    Assignee: The UAB Research Foundation
    Inventors: Lawrence S. Lamb, Jr., Antonio Di Stasi, G. Yancey Gillespie, Larisa Pereboeva
  • Patent number: 11421007
    Abstract: The present disclosure is in the field of modulation of Htt gene expression and HTT protein levels.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: August 23, 2022
    Assignees: Sangamo Therapeutics, Inc., CHDI Foundation, Inc.
    Inventors: Steven Froelich, Ignacio Munoz-Sanjuan, Edward J. Rebar, Bryan Zeitler, H. Steve Zhang
  • Patent number: 11401512
    Abstract: Described herein are engineered nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: August 2, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Russell DeKelver, Ivan Krivega, Jeffrey C. Miller, Lei Zhang
  • Patent number: 11401544
    Abstract: Methods and kits for preparing re-usable single cells are described. Cell components are anchored using a nano-scale scaffold to create a re-usable single cell. The nano-scale scaffold may be a polyacrylamide nano-scale scaffold. Methods to determine modifications of the genome, transcriptome, or epigenome are described.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: August 2, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Giovanna Tosato, Hidetaka Ohnuki